Sunscreen Ingredient TEA Decisions Highlight Challenges Of NDA Scale
This article was originally published in The Rose Sheet
Executive Summary
The TEA option has not provided a more efficient and economical method for drug industry stakeholders to convince FDA to expand OTC monographs with ingredients that have demonstrated safety records in foreign markets, but rather a system that rivals the rigors of the new drug application process. Former FDA attorneys offer perspective.